EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 1 (Janvier 2009) Med Sci (Paris), 25 1 (2009) 45-50 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 1, Janvier 2009
Page(s) 45 - 50
Section M/S revues
DOI https://doi.org/10.1051/medsci/200925145
Published online 15 January 2009
  1. Mezyk R, Bzowska M, Bereta J. Structure and functions of tumor necrosis factor-alpha converting enzyme. Acta Biochim Pol 2003; 50 : 625–45. [Google Scholar]
  2. Huovila APJ, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30 : 413–22. [Google Scholar]
  3. Blobel CP. ADAMS : key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6 : 32–43. [Google Scholar]
  4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29 : 258–89. [Google Scholar]
  5. Alfandari D, Cousin H, Gaultier A, Darribère T. Les protéines de la famille ADAM : protéolyse, adhérence et signalisation. Med Sci (Paris) 1999; 15 : 1148–51. [Google Scholar]
  6. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature 1997; 385 : 729–33. [Google Scholar]
  7. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385 : 733–6. [Google Scholar]
  8. Peiretti F, Deprez-Beauclair P, Bonardo B, et al. Identification of SAP97 as an intracellular binding partner of TACE. J Cell Sci 2003; 116 : 1949–57. [Google Scholar]
  9. Canault M, Tellier E, Bonardo B, et al. FHL2 interacts with both ADAM-17 and the cytoskeleton and regulates ADAM-17 localization and activity. J Cell Physiol 2006; 208 : 363–72. [Google Scholar]
  10. Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNF(alpha)-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005; 118 : 2371–80. [Google Scholar]
  11. Milla ME, Gonzales PE, Leonard JD. The TACE zymogen : re-examining the role of the cysteine switch. Cell Biochem Biophys 2006; 44 : 342–8. [Google Scholar]
  12. Peiretti F, Canault M, Deprez-Beauclair P, et al. Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. Exp Cell Res 2003; 285 : 278–85. [Google Scholar]
  13. Sagi I, Milla ME. Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-(alpha)-converting enzyme. Anal Biochem 2008; 372 : 1–10. [Google Scholar]
  14. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435 : 39–44. [Google Scholar]
  15. Matthews V, Schuster B, Schutze S, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003; 278 : 38829–39. [Google Scholar]
  16. Tellier E, Canault M, Rebsomen L, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006; 312 : 3969–80. [Google Scholar]
  17. Eissner G, Kolch W, Scheurich P. Ligands working as receptors : reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15 : 353–66. [Google Scholar]
  18. Horiuchi K, Kimura T, Miyamoto T, et al. Cutting edge : TNF-(alpha)-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 2007; 179 : 2686–9. [Google Scholar]
  19. Li N, Boyd K, Dempsey PJ, Vignali DAA. Non-cell autonomous expression of TNF-(alpha)-converting enzyme ADAM17 is required for normal lymphocyte development. J Immunol 2007; 178 : 4214–21. [Google Scholar]
  20. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997; 158 : 438–45. [Google Scholar]
  21. Mueller C, Corazza N, Trachsel-Loseth S, et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNF alpha) mediates effects distinct from those of wild-type TNF alpha in vitro and in vivo. J Biol Chem 1999; 274 : 38112–8. [Google Scholar]
  22. Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-(alpha). J Immunol 2002; 168 : 3394–401. [Google Scholar]
  23. Voros G, Maquoi E, Collen D, Lijnen HR. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-(alpha), TNF-(alpha) converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 2003; 1625 : 36–42. [Google Scholar]
  24. Smookler DS, Mohammed FF, Kassiri Z, et al. Cutting edge : tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006; 176 : 721–5. [Google Scholar]
  25. Tang ZY, Loss G, Carmody I, Cohen AJ. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation 2006; 82 : 1518–23. [Google Scholar]
  26. Purcell MK, Mu JL, Higgins DC, et al. Fine mapping of Ath6, a quantitative trait locus for atherosclerosis in mice. Mamm Genome 2001; 12 : 495–500. [Google Scholar]
  27. Holdt LM, Thiery J, Breslow JL, Teupser D. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008; 28 : 1097–103. [Google Scholar]
  28. Canault M, Peiretti F, Kopp F, et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice : possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006; 187 : 82–91. [Google Scholar]
  29. Canault M, Leroyer AS, Peiretti F, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-(alpha) converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007; 171 : 1713–23. [Google Scholar]
  30. Canault M, Peiretti F, Poggi M, et al. Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha. J Pathol 2008; 214 : 574–83. [Google Scholar]
  31. Fedak PWM, Moravec CS, McCarthy PM, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113 : 238–45. [Google Scholar]
  32. Shimoda Y, Satoh M, Nakamura M, et al. Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction. Clin Sci (Lond) 2005; 108 : 339–47. [Google Scholar]
  33. Morange P, Tregouet D, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality : the Athero Gene study. J Mol Med 2008; 86 : 1153–61. [Google Scholar]
  34. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32 (suppl 1) : 78–84. [Google Scholar]
  35. Xu H, Uysal KT, Becherer JD, et al. Altered tumor necrosis factor-(alpha) (TNF-[alpha]) processing in adipocytes and increased expression of transmembrane TNF-(alpha) in obesity. Diabetes 2002; 51 : 1876–83. [Google Scholar]
  36. Xu H, Hirosumi J, Uysal KT, et al. Exclusive action of transmembrane TNF(alpha) in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 2002; 143 : 1502–11. [Google Scholar]
  37. Lee K, Villena JA, Moon YS, et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003; 111 : 453–61. [Google Scholar]
  38. Serino M, Menghini R, Fiorentino L, et al. TNF-alpha converting enzyme heterozygous mice are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007; 56 : 2541–6. [Google Scholar]
  39. Togashi N, Ura N, Higashiura K, et al. Effect of TNF-(alpha)-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 2002; 39 : 578–80. [Google Scholar]
  40. Gelling RW, Yan W, Al-Noori S, et al. Deficiency of TNF(alpha) converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice. Endocrinology 2008; 149 : 6053–64. [Google Scholar]
  41. Federici M, Hribal ML, Menghini R, et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 2005; 115 : 3494–505. [Google Scholar]
  42. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight : tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008; 4 : 300–9. [Google Scholar]
  43. Surena AL, de Faria GP, Studler JM, et al. DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochim Biophys Acta 2008, 27 septembre online. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.